BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17634500)

  • 1. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.
    Lipshultz SE; Lipsitz SR; Orav EJ
    J Clin Oncol; 2007 Jul; 25(21):3179; author reply 3180. PubMed ID: 17634500
    [No Abstract]   [Full Text] [Related]  

  • 2. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
    Barry EV; Vrooman LM; Dahlberg SE; Neuberg DS; Asselin BL; Athale UH; Clavell LA; Larsen EC; Moghrabi A; Samson Y; Schorin MA; Cohen HJ; Lipshultz SE; Sallan SE; Silverman LB
    J Clin Oncol; 2008 Mar; 26(7):1106-11. PubMed ID: 18309945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence.
    Hellmann K
    J Clin Oncol; 2007 Oct; 25(29):4689-90; author reply 4690-1. PubMed ID: 17925567
    [No Abstract]   [Full Text] [Related]  

  • 5. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
    Friedberg JW
    Haematologica; 2008 Mar; 93(3):336-8. PubMed ID: 18310538
    [No Abstract]   [Full Text] [Related]  

  • 7. Do children have increased susceptibility for developing secondary acute myelogenous leukemia?
    Pyatt DW; Hays SM; Cushing CA
    Chem Biol Interact; 2005 May; 153-154():223-9. PubMed ID: 15878160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma].
    Borchmann P; Behringer K; Josting A; Rueffer JU; Schnell R; Diehl V; Engert A; Kvasnicka HM; Thiele J
    Pathologe; 2006 Feb; 27(1):47-52. PubMed ID: 16369761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapies in Hodgkin's lymphoma.
    Bartlett N
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):80, 83. PubMed ID: 16163165
    [No Abstract]   [Full Text] [Related]  

  • 10. Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
    Au WY; Chan LC; Liang R; Kwong YL
    Am J Hematol; 2006 Jun; 81(6):471-3. PubMed ID: 16680740
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
    Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
    Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faggot cells in an HIV-positive patient with inv(16)/therapy-related acute myeloid leukaemia.
    Jerez A; del Mar Osma M; Amigo M; Ortuño FJ
    Br J Haematol; 2010 Sep; 150(6):646. PubMed ID: 20666775
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiotherapy for early-stage Hodgkin's lymphoma: a 21st century perspective and review of multiple randomized clinical trials.
    Bar Ad V; Paltiel O; Glatstein E
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1472-9. PubMed ID: 19028275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Clavarezza M; Del Mastro L; Pronzato P; Bruzzi P; Venturini M
    J Natl Cancer Inst; 2007 Jul; 99(13):1050-1; author reply 1051-2. PubMed ID: 17596581
    [No Abstract]   [Full Text] [Related]  

  • 16. Carcinogenesis in Hodgkin's disease.
    Colman M
    Hematol Oncol; 1984; 2(1):2-4. PubMed ID: 6588020
    [No Abstract]   [Full Text] [Related]  

  • 17. Hodgkin lymphoma as second malignancy during continuing chemotherapy for childhood acute lymphoblastic leukemia.
    Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
    Klin Padiatr; 2008; 220(6):388-90. PubMed ID: 18949677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pediatric Oncology Group. Studies in Hodgkin's disease.
    Leventhal BG
    Cancer Treat Res; 1989; 41():257-62. PubMed ID: 2577079
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
    Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
    Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-related myeloid neoplasms.
    Czader M; Orazi A
    Am J Clin Pathol; 2009 Sep; 132(3):410-25. PubMed ID: 19687318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.